Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
ISR's Cash-to-Debt is ranked higher than
93% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. ISR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ISR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 21.92 Max: No Debt
Current: No Debt
Equity-to-Asset 0.86
ISR's Equity-to-Asset is ranked higher than
87% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ISR: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
ISR' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.09  Med: 0.82 Max: 0.91
Current: 0.86
-1.09
0.91
Piotroski F-Score: 5
Altman Z-Score: 2.24
Beneish M-Score: -2.91
WACC vs ROIC
9.05%
-100.14%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -132.47
ISR's Operating Margin % is ranked lower than
90% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.72 vs. ISR: -132.47 )
Ranked among companies with meaningful Operating Margin % only.
ISR' s Operating Margin % Range Over the Past 10 Years
Min: -132.47  Med: -100.36 Max: -56.56
Current: -132.47
-132.47
-56.56
Net Margin % -129.45
ISR's Net Margin % is ranked lower than
90% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.03 vs. ISR: -129.45 )
Ranked among companies with meaningful Net Margin % only.
ISR' s Net Margin % Range Over the Past 10 Years
Min: -141.24  Med: -92.01 Max: -54.25
Current: -129.45
-141.24
-54.25
ROE % -45.54
ISR's ROE % is ranked lower than
82% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.68 vs. ISR: -45.54 )
Ranked among companies with meaningful ROE % only.
ISR' s ROE % Range Over the Past 10 Years
Min: -69.15  Med: -45.7 Max: -16.5
Current: -45.54
-69.15
-16.5
ROA % -40.56
ISR's ROA % is ranked lower than
86% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.36 vs. ISR: -40.56 )
Ranked among companies with meaningful ROA % only.
ISR' s ROA % Range Over the Past 10 Years
Min: -52.98  Med: -39.79 Max: -14.86
Current: -40.56
-52.98
-14.86
ROC (Joel Greenblatt) % -116.53
ISR's ROC (Joel Greenblatt) % is ranked lower than
80% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.63 vs. ISR: -116.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ISR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -169.29  Med: -87.14 Max: -33.47
Current: -116.53
-169.29
-33.47
3-Year Revenue Growth Rate -4.20
ISR's 3-Year Revenue Growth Rate is ranked lower than
74% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.90 vs. ISR: -4.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ISR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 12.7
Current: -4.2
0
12.7
3-Year EBITDA Growth Rate -3.70
ISR's 3-Year EBITDA Growth Rate is ranked lower than
71% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. ISR: -3.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ISR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -24.3 Max: 401.3
Current: -3.7
0
401.3
3-Year EPS without NRI Growth Rate -11.20
ISR's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.90 vs. ISR: -11.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ISR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -30.7 Max: 278
Current: -11.2
0
278
GuruFocus has detected 1 Warning Sign with IsoRay Inc $ISR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ISR's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ISR Guru Trades in Q3 2016

Jeff Auxier 14,218 sh (unchged)
» More
Q4 2016

ISR Guru Trades in Q4 2016

Jeff Auxier 14,218 sh (unchged)
» More
Q1 2017

ISR Guru Trades in Q1 2017

Jeff Auxier 14,218 sh (unchged)
» More
Q2 2017

ISR Guru Trades in Q2 2017

Jeff Auxier 14,218 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ISR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:ATEC, NAS:PDEX, SGX:41A, ASX:ITD, XMCE:BIO, XKLS:0163, OTCPK:IGAP, XCNQ:LDS, NAS:CASM, OSTO:SDOS, TSE:7813, XKRX:241820, OSTO:INTEG B, LSE:ODX, ROCO:6493, BSP:BALM4, OTCPK:UEEC, NAS:BMRA, XKLS:0182, XKLS:7191 » details
Traded in other countries:AAJ.Germany,
Headquarter Location:USA
IsoRay Inc designs and develops personalized brachytherapy products. The company treats prostate cancer, brain, liver, breast cancer, colorectal cancer, gynecological cancer, lung cancer, ocular melanoma and pancreatic cancer.

IsoRay Inc designs and develops personalized brachytherapy products. The company treats prostate cancer, brain, liver, breast cancer, colorectal cancer, gynecological cancer, lung cancer, ocular melanoma and pancreatic cancer.

Top Ranked Articles about IsoRay Inc

IsoRay Announces Fourth Quarter Fiscal 2017 Revenue of $1.37 Million, 22% Fourth Quarter-over-Fourth Quarter Increase
IsoRay Announces Study Accepted for Publication in the International Journal of Radiation Oncology, Biology, Physics entitled "Re-irradiation using Permanent Interstitial Brachytherapy (PIB): A Potentially Durable Technique for Salvaging Recurrent Pelvic
IsoRay Announces "Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial" Poster Presentation at 2017 Annual American Society for Radiation Oncology (ASTRO) Conference
IsoRay Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017
IsoRay Announces Preliminary Fourth Quarter F2017 Revenue of $1.37 Million, 22% Year-over-Year Increase
New Study Shows Brachytherapy And Cesium-131 Isotope Treatment Beneficial For Prostate Cancer Patients
IsoRay Announces Study Published in The International Journal of Radiation Oncology, Biology, Physics entitled, "Clinical Outcomes of Large Brain Metastases Treated with Neurosurgical Resection and Intraoperative Cesium-131 Brachytherapy: Results of a Pro
IsoRay Announces Third Quarter Fiscal 2017 Financial Results
IsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology, Physics entitled "Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131"

Ratios

vs
industry
vs
history
PB Ratio 2.85
ISR's PB Ratio is ranked higher than
57% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. ISR: 2.85 )
Ranked among companies with meaningful PB Ratio only.
ISR' s PB Ratio Range Over the Past 10 Years
Min: 0.31  Med: 3.23 Max: 17.61
Current: 2.85
0.31
17.61
PS Ratio 6.33
ISR's PS Ratio is ranked lower than
70% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.36 vs. ISR: 6.33 )
Ranked among companies with meaningful PS Ratio only.
ISR' s PS Ratio Range Over the Past 10 Years
Min: 0.57  Med: 5.69 Max: 31.18
Current: 6.33
0.57
31.18
EV-to-EBIT -3.95
ISR's EV-to-EBIT is ranked lower than
99.99% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.17 vs. ISR: -3.95 )
Ranked among companies with meaningful EV-to-EBIT only.
ISR' s EV-to-EBIT Range Over the Past 10 Years
Min: -27.6  Med: -5.9 Max: 0.3
Current: -3.95
-27.6
0.3
EV-to-EBITDA -4.02
ISR's EV-to-EBITDA is ranked lower than
99.99% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.83 vs. ISR: -4.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
ISR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.4  Med: -7.2 Max: 0.3
Current: -4.02
-31.4
0.3
EV-to-Revenue 5.11
ISR's EV-to-Revenue is ranked lower than
60% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. ISR: 5.11 )
Ranked among companies with meaningful EV-to-Revenue only.
ISR' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.3  Med: 5.15 Max: 39
Current: 5.11
-0.3
39
Current Ratio 9.30
ISR's Current Ratio is ranked higher than
93% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.57 vs. ISR: 9.30 )
Ranked among companies with meaningful Current Ratio only.
ISR' s Current Ratio Range Over the Past 10 Years
Min: 0.07  Med: 5.53 Max: 16.65
Current: 9.3
0.07
16.65
Quick Ratio 9.01
ISR's Quick Ratio is ranked higher than
95% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. ISR: 9.01 )
Ranked among companies with meaningful Quick Ratio only.
ISR' s Quick Ratio Range Over the Past 10 Years
Min: 0.06  Med: 4.79 Max: 16.34
Current: 9.01
0.06
16.34
Days Inventory 32.23
ISR's Days Inventory is ranked higher than
93% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.23 vs. ISR: 32.23 )
Ranked among companies with meaningful Days Inventory only.
ISR' s Days Inventory Range Over the Past 10 Years
Min: 29.03  Med: 39.96 Max: 64.02
Current: 32.23
29.03
64.02
Days Sales Outstanding 55.66
ISR's Days Sales Outstanding is ranked higher than
60% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.37 vs. ISR: 55.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.3  Med: 58.77 Max: 83.13
Current: 55.66
46.3
83.13

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.20
ISR's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.10 vs. ISR: -0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ISR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -110.2  Med: -14.5 Max: 0
Current: -0.2
-110.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.88
ISR's Price-to-Net-Cash is ranked higher than
75% of the 52 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.35 vs. ISR: 6.88 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ISR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.92  Med: 16 Max: 53.51
Current: 6.88
1.92
53.51
Price-to-Net-Current-Asset-Value 3.44
ISR's Price-to-Net-Current-Asset-Value is ranked higher than
77% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.73 vs. ISR: 3.44 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ISR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.25  Med: 6.38 Max: 175
Current: 3.44
1.25
175
Price-to-Tangible-Book 2.89
ISR's Price-to-Tangible-Book is ranked higher than
66% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.82 vs. ISR: 2.89 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ISR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.59  Med: 3.98 Max: 53.47
Current: 2.89
0.59
53.47
Price-to-Median-PS-Value 1.10
ISR's Price-to-Median-PS-Value is ranked higher than
58% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. ISR: 1.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ISR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 1.18 Max: 5.38
Current: 1.1
0.19
5.38
Earnings Yield (Greenblatt) % -25.32
ISR's Earnings Yield (Greenblatt) % is ranked lower than
92% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. ISR: -25.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ISR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7210.5  Med: -16.7 Max: 16057.5
Current: -25.32
-7210.5
16057.5

More Statistics

Revenue (TTM) (Mil) $4.76
EPS (TTM) $ -0.11
Beta1.12
Short Percentage of Float0.26%
52-Week Range $0.48 - 0.71
Shares Outstanding (Mil)55.02

Analyst Estimate

Jun20
Revenue (Mil $)
EPS ($) 0.09
EPS without NRI ($) 0.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}